These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14682275)

  • 21. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

  • 22. Fusion inhibitors: T-20 and T-1249.
    TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
    [No Abstract]   [Full Text] [Related]  

  • 23. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Prognosis after triple-class failure.
    Currier J
    AIDS Clin Care; 2003 Nov; 15(11):95. PubMed ID: 14682274
    [No Abstract]   [Full Text] [Related]  

  • 24. FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?
    Sharp M; Camp R
    GMHC Treat Issues; 2003 Mar; 17(3):7-8. PubMed ID: 12728858
    [No Abstract]   [Full Text] [Related]  

  • 25. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
    Polk C; Chan-Tack KM; Kopack AM; Amoroso A
    AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
    [No Abstract]   [Full Text] [Related]  

  • 26. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
    James JS
    AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880
    [No Abstract]   [Full Text] [Related]  

  • 27. New package inserts for efavirenz and T-20.
    AIDS Clin Care; 2007 Mar; 19(3):24. PubMed ID: 17595717
    [No Abstract]   [Full Text] [Related]  

  • 28. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 29. Enfuvirtide, an HIV-1 fusion inhibitor.
    Jenny-Avital ER
    N Engl J Med; 2003 Oct; 349(18):1770-1; author reply 1770-1. PubMed ID: 14593994
    [No Abstract]   [Full Text] [Related]  

  • 30. T-20 and adefovir for salvage therapy -- expect no miracles.
    Gilden D
    GMHC Treat Issues; 1998 Apr; 12(4):6-7. PubMed ID: 11365400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fresh data on new anti-HIV drugs presented in Durban.
    Leibovich M
    Posit Living; 2000 Aug; 9(7):16-7. PubMed ID: 12492026
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-HIV agents. Needle-free T-20.
    TreatmentUpdate; 2005; 17(5):9-10. PubMed ID: 17219660
    [No Abstract]   [Full Text] [Related]  

  • 33. First fusion inhibitor for advanced HIV.
    Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877130
    [No Abstract]   [Full Text] [Related]  

  • 34. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 36. David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.
    Reddy D
    Lancet Infect Dis; 2003 Feb; 3(2):110-3. PubMed ID: 12560198
    [No Abstract]   [Full Text] [Related]  

  • 37. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug.
    Sax PE
    AIDS Clin Care; 2003 Nov; 15(11):93-4. PubMed ID: 14682271
    [No Abstract]   [Full Text] [Related]  

  • 38. Long path to approval. A look back at the road to Fuzeon.
    GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856
    [No Abstract]   [Full Text] [Related]  

  • 39. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
    Charpentier C; Joly V; Ghosn J; Yeni P; Raffi F; Descamps D; Morand-Joubert L
    J Antimicrob Chemother; 2014 Sep; 69(9):2588-90. PubMed ID: 24816213
    [No Abstract]   [Full Text] [Related]  

  • 40. T-20 continues to look promising.
    AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.